Literature DB >> 760749

Haemodynamic effects and plasma concentrations of labetalol during long-term treatment of essential hypertension.

P Lund-Johansen, O M Bakke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 760749      PMCID： PMC1429429          DOI： 10.1111/j.1365-2125.1979.tb00917.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  14 in total

1.  Haemodynamic long-term effects of atenolol at rest and during exercise in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Haemodynamic long-term effects of prazosin plus tolamolol in essential hypertension.

Authors:  P Lund-Johansen
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

3.  Double-blind trial of labetalol.

Authors:  J Kane; I Gregg; D A Richards
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

4.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

Review 5.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.

Authors:  R T Brittain; G P Levy
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  Relationship between plasma concentrations and pharmacological effects of labetalol.

Authors:  D A Richards; J G Maconochie; R E Bland; R Hopkins; E P Woodings; L E Martin
Journal:  Eur J Clin Pharmacol       Date:  1977-01-03       Impact factor: 2.953

Review 7.  Pharmacological effects of labetalol in man.

Authors:  D A Richards
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

8.  Haemodynamic effects of long-term oral labetalol.

Authors:  R C Edwards; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Experience with labetalol in hypertension.

Authors:  P Bolli; J Waal-Manning; A J Wood; F O Simpson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

10.  Acute haemodynamic effects of labetalol and its subsequent use of an oral hypotensive agent.

Authors:  A M Joekes; F D Thompson
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335
View more
  14 in total

1.  Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin.

Authors:  P Lund-Johansen
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

2.  Hemodynamic effects of antihypertensive agents.

Authors:  P Lund-Johansen
Journal:  Can Med Assoc J       Date:  1983-01-01       Impact factor: 8.262

3.  Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy.

Authors:  G L Sanders; P A Routledge; A Ward; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

4.  Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment.

Authors:  G L Sanders; D M Davies; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1980-08       Impact factor: 4.335

5.  Magnitude and mechanisms of the antihypertensive action of labetalol, including ambulatory assessment.

Authors:  G R Bellamy; S N Hunyor; D Roffe; J Massang
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

6.  Acute and long-term effects of labetalol on systemic and pulmonary haemodynamics in hypertensive patients.

Authors:  T L Svendsen; S Rasmussen; O J Hartling; P E Nielsen; J Trap-Jensen
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

7.  A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

8.  Response of the systemic pulmonary circulation to labetalol at rest and during exercise.

Authors:  R Fagard; P Lijnen; A Amery
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of labetalol.

Authors:  J J McNeil; W J Louis
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.

Authors:  R Donnelly; G J Macphee
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.